SS-31

SS-31, also called elamipretide or MTP-131, is a synthetic four-amino-acid peptide studied for its effects on mitochondria. These structures help cells produce ATP, a usable form of cellular energy. Elamipretide interacts with cardiolipin, a lipid in the inner mitochondrial membrane; the Forzinity prescribing information describes it as a mitochondrial cardiolipin binder.

The molecule and a particular product should not be treated as interchangeable. Forzinity is approved in the United States to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. That indication does not establish general anti-aging benefits for other SS-31 preparations.

Research spans rare mitochondrial disease, heart failure and aging-related mitochondrial changes. The results are not uniformly positive: a small older-adult study found an acute mitochondrial-energy signal, while the larger MMPOWER-3 trial did not meet its walking-distance or fatigue endpoints. Reports of greater energy or better recovery outside trials are anecdotal, not predictable outcomes.

Cardiolipin helps organize the inner mitochondrial membrane and the machinery involved in energy production. Elamipretide research examines how interaction with this membrane can affect mitochondrial efficiency and oxidative stress. The human mitochondrial study tested a measurable energy-production response rather than assuming that a plausible mechanism guarantees a clinical benefit.

Mechanistic effects have been demonstrated under specific experimental conditions. In an eight-week study in aged mice, SS-31 improved mitochondrial energetics and redox balance without increasing mitochondrial content. This supports further investigation; it does not show that every tissue in every person responds similarly.

A change in ATP production, an improvement in muscle performance and a reduction in disease complications are different outcomes. The older-adult trial illustrates that distinction: an acute mitochondrial signal did not translate into a significant immediate benefit on its main fatigue-resistance measure. Mechanistic promise should not be presented as proof of cognitive enhancement, superiority to antioxidants or longer life.

Animal findings: The aged-mouse study reported improved muscle fatigue resistance and treadmill endurance after eight weeks. A subsequent 2025 mouse study found favorable changes in frailty and some cardiac and muscle-function measures, but no consistent reduction in epigenetic or transcriptomic age. Better function and a younger molecular-age measurement are not the same claim.

Early human research: A randomized study of 39 adults aged 60–85, selected for poorly functioning muscle mitochondria, tested a single two-hour IV infusion. The relative change in mitochondrial ATP-production capacity favored elamipretide, while the absolute-change analysis narrowly missed conventional statistical significance. The difference was not sustained at day seven, and the main immediate fatigue-resistance measure did not significantly improve. This is an encouraging physiological signal, not evidence of generalized rejuvenation.

Energy and metabolic experiences: Reports of increased vigor, better workouts or improved body composition outside trials remain anecdotal. The human energy-production experiment did not establish weight loss, improved insulin sensitivity or a reliable everyday-energy benefit. Nor does mitochondrial targeting alone establish that combining SS-31 with NAD+ precursors, other peptides or supplements is effective.

Heart failure: an early signal. In a 36-person randomized dose-escalation trial, a single four-hour IV infusion produced favorable acute ventricular-volume changes in the highest-dose group compared with placebo. No serious adverse events were reported in that small acute study. It did not establish a long-term reduction in hospitalization or mortality.

Heart failure: a later neutral result. PROGRESS-HF randomized 71 patients with stable heart failure and reduced ejection fraction to daily subcutaneous elamipretide or placebo for 28 days. Neither active-dose group significantly improved the primary left-ventricular end-systolic-volume endpoint, and ejection-fraction changes did not significantly differ. The early infusion findings therefore should not be generalized into proven ongoing heart-failure protection.

Primary mitochondrial myopathy: early patient-reported benefits. MMPOWER-2 was a 30-person crossover trial with four weeks of treatment per arm. The walking-distance advantage did not reach statistical significance, while several patient-reported fatigue measures favored treatment. Those secondary signals helped justify a larger trial; they were not definitive proof of efficacy.

Primary mitochondrial myopathy: the larger trial. MMPOWER-3 randomized 218 adults to daily subcutaneous elamipretide or placebo for 24 weeks. Neither the walking-distance nor fatigue coprimary endpoint improved significantly. A favorable walking-distance finding in a genetic subgroup was post hoc and should be treated as a research lead, not the overall trial result.

Safety observations remain study-specific. Injection-site reactions were common in MMPOWER-2 and MMPOWER-3, often mild or moderate. MMPOWER-3 reported serious adverse events in both groups, none judged treatment-related. This differs from saying serious events never occur, and does not override product-specific warnings.

Product-specific prescribing: Forzinity's labeled regimen is 40 mg subcutaneously daily for eligible Barth syndrome patients. Adults with eGFR below 30 mL/min who are not on dialysis receive 20 mg daily; dosing information is insufficient for dialysis or pediatric renal impairment. These are not anti-aging recommendations.

Formulation and handling: Forzinity is a ready-to-use 80 mg/mL solution, not a powder requiring reconstitution or an IV product. Do not mix medicines in its syringe. Refrigerate unopened vials at 2–8°C; opened vials may be refrigerated or kept at 20–25°C and must be discarded after eight days. Do not freeze. These instructions are formulation-specific.

Research exposure is not a universal protocol: The heart-failure infusion study and subcutaneous myopathy trial used different routes and schedules. They do not support a standard 0.05–0.1 mg injection two or three times weekly, a universal 24–48-hour peak, or a validated anti-aging cycle or supplement stack.

Important safety distinction: Forzinity can cause serious hypersensitivity: stop further doses, seek immediate care for an immediate reaction and do not rechallenge after a serious reaction. Its benzyl-alcohol-containing formulation is not for neonates. Trial tolerability is not a guarantee of safety across other products or circumstances.

Barth syndrome is a rare genetic disorder involving abnormal cardiolipin remodeling. The TAZPOWER trial studied 12 participants using two 12-week crossover periods separated by a four-week washout. Elamipretide did not significantly outperform placebo on walking distance, fatigue or the reported secondary endpoints during that controlled phase.

Ten participants entered the open-label extension, with eight evaluated at week 36. The original report described improved walking distance, fatigue and strength relative to baseline, as well as encouraging cardiac observations. Those findings lacked a concurrent placebo group; they do not establish a reduction in hospitalizations or prove broader heart-failure prevention.

The US muscle-strength indication received accelerated approval based on knee-extensor strength, an intermediate clinical endpoint; continued approval may depend on confirmatory evidence. This is a meaningful disease-specific development, not proof that SS-31 reverses aging in otherwise healthy people.